Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

TITAN PHARMACEUTICAL INC (TTNP)

Biological Products, (no Disgnostic Substances)

https://www.titanpharm.com

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

400 OYSTER POINT BLVD, SUITE 505
SAN FRANCISCO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/17/1996

Market Cap

4,635,166

Shares Outstanding

750,000

Weighted SO

753,314

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

FWBI --.--%

SLRX --.--%

SABS --.--%

VCNX --.--%

GOVX --.--%

SNTI --.--%

ZIVO --.--%

CVKD --.--%

Beta

1.1760

Last Div

0.0000

Range

4.24-11.4

Chg

-0.3400

Avg Vol

7153

Mkt Cap

4635166

Exch

NASDAQ

Country

US

Phone

650 244 4990

DCF Diff

-0.6330

DCF

5.7030

Div Yield

0.0000

P/S

54.5314

EV Multiple

-0.0615

P/FV

1.1602

Div Yield %

0.0000

P/E

-0.8486

PEG

-0.0166

Payout

0.0000

Current Ratio

12.2191

Quick Ratio

12.2191

Cash Ratio

11.4944

DSO

163.1765

DIO

0.0000

Op Cycle

163.1765

DPO

4060.6250

CCC

-3897.4485

Gross Margin

0.6235

Op Margin

-83.8706

Pretax Margin

-64.2471

Net Margin

-64.2471

Eff Tax Rate

0.0022

ROA

-1.2554

ROE

-0.8788

ROCE

-1.7849

NI/EBT

1.0000

EBT/EBIT

0.7660

EBIT/Rev

-83.8706

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

-324.0455

CF/Debt

0.0000

Equity Multi

1.0891

Rec Turnover

2.2368

Pay Turnover

0.0899

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0195

OCF/Share

-5.1357

FCF/Share

-5.1379

Cash/Share

4.4770

OCF/Sales

-55.2235

FCF/OCF

1.0004

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

-2347.0000

Div&CapEx Cov

-2347.0000

P/BV

1.1602

P/B

1.1602

P/S

54.5314

P/E

-0.8486

P/FCF

-0.9870

P/OCF

-0.9872

P/CF

-0.9872

PEG

-0.0166

P/S

54.5314

EV Multiple

-0.0615

P/FV

1.1602

DPS

0.0000

Latest Headlines (EST)

Benzinga Dec 29, 12:19 Nasdaq Down Over 100 Points; Fortress Biotech Shares Plummet GlobeNewswire Inc. Dec 28, 16:15 Titan Pharmaceuticals Announces Reverse Stock Split and Ratio GlobeNewswire Inc. Dec 28, 16:15 Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

Revenue Product Segmentation